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Dear Editor,
Atypical hemolytic–uremic syndrome (aHUS) is an extremely
rare, genetic, chronic, and progressive inﬂammatory disease1
caused by defects in complement system. These defects result
in systemic thrombotic microangiopathy involving damage
to multiple organ systems including renal dysfunction.1–7
Genetic mutations have been detected in around 50% of the
reported cases. Regarding renal transplant patients, expanded
criteria donors, infection by cytomegalovirus or BK, use of
CNI or m-TOR  inhibitors and antibody-mediated rejection
(AMR) have been related to de novo post-transplant aHUS.8
Graft failure is reported in 60–90% of patients within 1 year.10
Eculizumab is a monoclonal antibody that binds to C5 com-
plement protein avoiding the formation of the cell membrane
attack complex.6,7 We report herein a case of late onset of de
novo post-transplant aHUS on a simultaneous pancreas and
kidney recipient with severe systemic manifestations, with-
out presenting acute graft rejection, successfully treated with
limited doses of eculizumab remaining stable after one year
of follow-up.
A 46-year-old woman with end stage renal disease
secondary to type 1 Diabetes Mellitus underwent simul-
taneous pancreas and kidney transplant on October 2012
from deceased donor. Received induction with Basiliximab
and maintenance treatment with mycophenolate mofetil,
tacrolimus, and prednisone. Pancreatic and renal function
were stable, creatinine (SCr) of 110 mol/L. Tacrolimus through
levels remained between 6 and 8 ng/ml. Seven months
after transplant presented fever, abdominal pain, diarrheamolytic–uremic  syndrome
ncreas  and  kidney
 treated  with  eculizumab
olítico–urémico  atípico  de  novo
ático  resuelto  con  eculizumab
and vomiting, acute graft dysfunction (SCr 438 mol/L) and
thrombocytopenia (53 × 10 × 9/L). She developed progressive
anemia and thrombocytopenia and worsening of renal func-
tion requiring dialysis. Pancreas graft function remained
preserved. Thrombotyc microangiopathy (TMA)was detected
with lactate dehydrogenase (LDH) up to 1500 UI/L, unde-
tectable haptoglobin and schistocytes. C3 was low, ADAMTS 13
of 79% and Shigella toxin was negative. Urinary tract infection
by extended-spectrum beta-lactamase (ESBL)-klebsiella was
present. Initial biopsy conﬁrmed ﬁndings of TMA  with severe
tubulo-interstitial involvement and some focal glomerular
involvement, without features of acute rejection. Discontin-
uation of tacrolimus, antibiotic treatment with meropenem
and daily plasma exchange (PE) for 10 days were performed.
The patient did not respond to therapy. Second renal biopsy
showed persistent signs of TMA, worsening involvement of
glomeruli with mesangiolysis without rejection (Fig. 1). Treat-
ment with Eculizumab was started with 4 doses of 900 mgrenal function, cessation of hemodialysis and hemolysis.
Genetic screening did not detect mutations on factor I, factor
H or factor MCP genes. Risk haplotype in heterozygosis for fac-
tor H and MCP genes were observed. Study of the complement
alternate pathway showed low factor C3, factor H, normal
expression of MCP  (membrane cofactor protein) and nega-
tive anti-factor H antibodies. A third biopsy was performed
showing predominance of chronic lessions of TMA  and mild
signs of acute TMA with interstitial ﬁbrosis of 5–10% and some
microhemorrhages, with ATN (Fig. 2). New course of 3 daily PE
and ﬁnal dose of 1200 mg  of Eculizumab iv were prescribed.
n e f r o l o g i a. 2 0 1 6;3  6(3):318–332 329
Fig. 1 – Acute TMA  showing thrombosis at glomerular
capillaries and mesangiolysis (Masson’s trichrome stain).
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symptoms. This highlights the importance of an early diag-
nosis and promptly treatment with eculizumab in order to
improve renal and systemic results. In our case limited doses
of eculizumab provided sustained improvement. Further evi-
dence is needed to establish the optimal dosing in different
clinical settings.
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